Explain this page
Arphra AIPlain-English read on DexCom, Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$320.16
+339.42% vs spot
Recommendation
Strong Buy
15 of 16 methods
Method spread
4bull11bear
±5% threshold
Analyst PT consensus: $80.88 (+11.01%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.37% | -0.86% | +20.71% | +6.99% | +11.25% | +9.78% | -15.93% | -41.89% | -24.69% | +325.09% | +2378.23% |
Insider · 30d
History →Bought
$1M
2 txns
Sold
$905.63K
8 txns
Net flow
+$96.07K
Aftermarket
LiveLast trade
$72.33
Bid
$71.54
80 sh
Ask
$75.50
50 sh
Spread
$3.960
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $1.19B | $199.5M | $0.51 |
| Q4 Dec 2025 | $1.26B | $267.3M | $0.68 |
| Q3 Sep 2025 | $1.21B | $283.8M | $0.70 |
| Q2 Jun 2025 | $1.16B | $179.8M | $0.45 |
| Q1 Mar 2025 | $1.04B | $105.4M | $0.27 |
| Q4 Dec 2024 | $1.11B | $151.7M | $0.38 |
Analyst view
DB · price_targets + analyst_gradesConsensus target
$80.88
+11.01% upside
Low
$67.00
Median
$78.50
High
$100.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in studyreuters.com·Jun 06, 2026
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulinbusinesswire.com·Jun 06, 2026
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulinbusinesswire.com·Jun 06, 2026
- Here's Why You Should Retain DexCom Stock in Your Portfoliozacks.com·Jun 04, 2026
- DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?fool.com·Jun 04, 2026
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026gurufocus.com·Jun 04, 2026
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026businesswire.com·Jun 04, 2026
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026businesswire.com·Jun 04, 2026
Peers
- TEVATeva Pharmaceutical Industries Limited$34.95$40.7B
- BIIBBiogen Inc.$187.06$27.62B
- PHGKoninklijke Philips N.V.$26.16$24.89B
- WSTWest Pharmaceutical Services, Inc.$300.68$21.24B
- LHLabcorp Holdings Inc.$255.84$21.06B
- STESTERIS plc$214.40$21.04B
- WATWaters Corporation$307.12$18.28B
- ZBHZimmer Biomet Holdings, Inc.$82.90$16.05B
Total assets
$6.34B
Total debt
$1.39B
Cash & equiv
$917.7M
Operating CF
$1.44B
Free cash flow
$1.08B
Buybacks
-$500M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Brown Michael Jon officer: EVP, Chief Legal Officer | Sell | 1,700 | $107.17K | Apr 15, 2026 |
Brown Michael Jon officer: EVP, Chief Legal Officer | Sell | 1,700 | $110.25K | Mar 16, 2026 |
Heller Bridgette P director | Sell | 1,012 | $68.83K | Feb 12, 2026 |
Collins Richard Alexander director | Sell | 2,906 | $171.6K | Nov 14, 2025 |
Heller Bridgette P director | Sell | 1,012 | $58.77K | Nov 12, 2025 |
Leach Jacob Steven officer: President & COO | Buy | 2,500 | $138.56K | Nov 10, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $4.66B | $911.8M | $836.3M | $2.09 | +17.94% |
| FY 2024 | $4.03B | $600M | $576.2M | $1.42 | +14.29% |
| FY 2023 | $3.62B | $597.7M | $541.5M | $1.30 | +14.95% |
| FY 2022 | $2.91B | $391.2M | $341.2M | $0.80 | +11.73% |
| FY 2021 | $2.45B | $265.8M | $216.9M | $0.51 | +8.86% |